Onxeo SA

Onxeo SA is a clinical-stage biotechnology company based in France and the United States. As a small company with three employees, Onxeo focuses its efforts on developing innovative cancer treatments. They generate revenue of $5 million annually. Onxeo specializes in developing new cancer drugs by targeting tumor DNA functions through unique mechanisms of action in the field of DNA Damage Response (DDR). Their approach aims to weaken or block the ability of tumor cells to repair DNA damage, either naturally or under the effects of cytotoxic treatments. Onxeo's product portfolio includes AsiDNA™, a first-in-class product that interferes with tumor DNA break repair, and a new family of compounds, OX400, designed as new-generation PARP agonists. Onxeo's platform, platON™, utilizes decoy oligonucleotide technology to generate new compounds based on a unique DDR decoy mechanism. This innovative technology, developed through extensive preclinical and translational research, positions Onxeo at the forefront of cancer treatment research. For more information about Onxeo SA and their groundbreaking cancer therapies, visit their website at onxeo.com.